Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Review Article

Open Access Gateway

The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function

Goossens G.H.

Author affiliations

Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands

Corresponding Author

Gijs H. Goossens, PhD

Department of Human Biology

NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center

PO Box 616, 6200 MD, Maastricht, The Netherlands

G.Goossens@maastrichtuniversity.nl

Related Articles for ""

Obes Facts 2017;10:207-215

Abstract

The current obesity epidemic poses a major public health issue since obesity predisposes towards several chronic diseases. BMI and total adiposity are positively correlated with cardiometabolic disease risk at the population level. However, body fat distribution and an impaired adipose tissue function, rather than total fat mass, better predict insulin resistance and related complications at the individual level. Adipose tissue dysfunction is determined by an impaired adipose tissue expandability, adipocyte hypertrophy, altered lipid metabolism, and local inflammation. Recent human studies suggest that adipose tissue oxygenation may be a key factor herein. A subgroup of obese individuals - the ‘metabolically healthy obese' (MHO) - have a better adipose tissue function, less ectopic fat storage, and are more insulin sensitive than obese metabolically unhealthy persons, emphasizing the central role of adipose tissue function in metabolic health. However, controversy has surrounded the idea that metabolically healthy obesity may be considered really healthy since MHO individuals are at increased (cardio)metabolic disease risk and may have a lower quality of life than normal weight subjects due to other comorbidities. Detailed metabolic phenotyping of obese persons will be invaluable in understanding the pathophysiology of metabolic disturbances, and is needed to identify high-risk individuals or subgroups, thereby paving the way for optimization of prevention and treatment strategies to combat cardiometabolic diseases.

© 2017 The Author(s) Published by S. Karger GmbH, Freiburg


Keywords

Oxygen · Obesity · Body fat · Adipose tissue function · Metabolic health ·


Introduction

Obesity is currently one of the main public health concerns since it is a major contributor to the global burden of chronic diseases, including cardiovascular disease, non-alcoholic fatty liver disease, type 2 diabetes mellitus, and certain types of cancer [1]. Insulin resistance in peripheral tissues and pancreatic beta-cell dysfunction are key factors in the development of type 2 diabetes. Although the relative contributions of these parameters to the pathophysiology of type 2 diabetes have been debated extensively, it is well established that a feedback loop exists between insulin sensitive peripheral organs and the pancreatic beta-cell [2]. The hyperbolic relationship between insulin sensitivity and insulin secretion explains the markedly increased insulin response in insulin resistant as compared to insulin sensitive subjects [3]. Normoglycemia is maintained in situations where the compensatory increase in insulin secretion is sufficient to overcome peripheral insulin resistance. However, failure of this compensatory insulin response will lead to impaired glucose metabolism and may eventually result in overt type 2 diabetes [2,3]. Therefore, it is of utmost importance to better understand the pathophysiological basis for both insulin resistance and beta-cell dysfunction in humans. The aim of the present review is to provide an adipocentric view on the pathophysiology of insulin resistance in humans. More specific, the importance of total fat mass, body fat distribution, and adipose tissue function in the metabolic phenotype of obese individuals will be highlighted, and the clinical relevance thereof will be addressed. In addition, the putative role of adipose tissue oxygenation in adipose tissue biology and metabolic health will be discussed.

Detailed Metabolic Phenotyping in Obesity: Paving the Way Forward

BMI

The BMI, which is an anthropometric index that is used as a surrogate marker for fat mass and for classifying obesity, is positively associated with risk factors for cardiovascular and metabolic diseases when BMI is above 18.5 kg/m2. Importantly, the relationship between BMI and body fat mass is not sufficiently strong to accurately estimate adiposity in a particular individual since BMI does not take body composition (i.e., skeletal muscle mass) into account. Therefore, if the amount of fat mass is the true risk factor for cardiometabolic health and longevity, then the use of BMI is only an approximation and is therefore inadequate [4]. The use of BMI as an indicator of metabolic health is even more problematic in older obese persons with decreased muscle mass and strength, i.e. sarcopenic obese patients, who are at special risk for adverse outcomes [5]. Based on the most recent prospective data from the Global BMI Mortality Collaboration, a BMI of 20.0-25.0 kg/m2 is associated with the lowest mortality rate [6]. Noteworthy, the latter analysis limited confounding and reverse causality by restricting analyses to never-smokers, excluding subjects with known pre-existing chronic disease and omitting the initial 5 years of follow-up. The use of universal BMI cut-off points to classify subjects as normal weight, overweight and obese, however, do not consistently reflect adiposity in different ethnic populations. This may be particularly problematic for South Asian populations, displaying a greater proportion of body fat for a given BMI than Caucasians [7]. The latter is in agreement with the higher susceptibility to develop type 2 diabetes and coronary artery disease in South Asians in spite of lower BMI [8]. The value of BMI as a marker for obesity and indicator of metabolic health has been extensively debated and is discussed in more detail elsewhere [4]. Currently, more sensitive techniques to determine body composition are available, and phenotyping beyond BMI is clearly needed to accurately assess metabolic health at an individual level.

Fat Mass

Although total fat mass is a more accurate measure of the metabolic phenotype than BMI, the absolute amount of body fat does not unambiguously reflect metabolic health at an individual level. This is exemplified by the finding that abdominal liposuction, which is the surgical removal of subcutaneous adipose tissue in the abdominal region, does not significantly improve obesity-associated metabolic abnormalities such as insulin resistance in humans [9]. Furthermore, pharmacological treatment with thiazolidinediones (peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists) improve insulin sensitivity in humans, despite significant fat mass gain [10]. Another condition in which the association between adipose tissue mass and metabolic health might seem paradoxical is lipodystrophy. A deficiency of adipose tissue, as in patients with (partial) lipodystrophy, is also associated with insulin resistance and a high incidence of type 2 diabetes [11]. Indeed, lipodystrophic mice are severely insulin resistant [12], and surgical implantation of adipose tissue from healthy mice into lipodystrophic animals reversed insulin resistance in a dose-dependent manner [13]. Taken together, excessive adipose tissue mass as well as a (partial) lack of adipose tissue are related to insulin resistance and predispose towards chronic cardiometabolic diseases. This implies that total adipose tissue mass is not the predominant factor that explains the increased metabolic risk in obese individuals. Rather, the location where the excessive calories are stored in combination with adipose tissue function seem to determine metabolic health.

Body Fat Distribution

Body fat distribution is a strong metabolic and cardiovascular risk factor. The mechanisms that underlie inter-individual differences in body fat distribution are complex and remain to be elucidated although evidence indicates that sex hormones [14], use of glucocorticoids [15], genetic make-up [16], and epigenetic mechanisms [17,18,19] determine where the excessive calories from the diet are stored. Accumulation of adipose tissue in the upper body (abdominal region) is associated with the development of obesity-related comorbidities and even all-cause mortality. In contrast, population studies have shown that accumulation of fat in the lower body (gluteofemoral region) is associated with a protective lipid and glucose profile as well as a decrease in cardiovascular and metabolic disease prevalence after adjustment for total body fat mass [20,21]. These differences in disease risk are due to strikingly divergent functional properties of these adipose tissue depots as will be discussed in the next section.

Adipose Tissue Function

Adipose tissue is the main lipid storage depot in our body and, as such, has a crucial role in buffering the daily influx of dietary fat entering the circulation [22,23]. Thus, the ability of our body to adapt to (chronic) changes in caloric intake largely depends on the ability of adipose tissue to accommodate a potential excess of calories. In obesity, the subcutaneous adipose tissue may fail to appropriately expand to store the energy surplus. This in turn may lead to ectopic fat deposition in other tissues involved in metabolic homeostasis (i.e., skeletal muscle, the liver, and visceral adipose tissue) and, consequently, insulin resistance [22,24,25] (fig. 1). Therefore, the expandability of subcutaneous adipose tissue seems to be a critical factor in the development of insulin resistance [26] although this concept is mainly based on cross-sectional findings and has recently been challenged by an 8-week overfeeding study in humans [27]. Thus, lipids may be predominantly stored in subcutaneous adipose tissue before marked expansion of the visceral adipose tissue depot occurs although inter-individual differences in the fat storage pattern within a certain population may occur. The factors underlying impaired adipose tissue expandability are not yet fully understood, but the properties of its extracellular matrix and angiogenic capacity seem to be involved [28]. Interestingly, in contrast to the belief that inflammatory signals exert a fundamentally negative impact on metabolism, there is evidence in rodents that pro-inflammatory signaling in adipose tissue is required for proper adipose tissue remodeling and expansion [29]. It has been shown that adipose tissue-specific reduction in pro-inflammatory potential in mice reduced in vivo adipogenic capacity, which was associated with ectopic lipid accumulation, glucose intolerance, and systemic inflammation [29]. These data suggest that adipose tissue inflammation may be an adaptive response that enables safe storage of excess nutrients in adipose tissue, thereby protecting against metabolic and inflammatory perturbations.

Fig. 1

Differences in adipose tissue function and body fat distribution between MHO and metabolically unhealthy obese individuals. Expansion of adipose tissue does not necessarily translate into metabolic abnormalities. A subgroup of individuals with obesity, referred to as MHO individuals, is relatively protected against the development of cardiometabolic diseases as compared to metabolically unhealthy obese subjects. Emerging evidence suggests that alterations in adipose tissue function and body fat distribution are key factors underlying the metabolically unhealthy obese phenotype. Metabolically unhealthy obese individuals are characterized by lower subcutaneous fat mass, adipocyte hypertrophy, a pro-inflammatory adipose tissue phenotype and an impaired fat storage capacity of adipose tissue, which may result in ectopic fat deposition (i.e., more visceral fat, lipid accumulation in the liver and skeletal muscle) and inflammation in visceral adipose tissue, thereby contributing to the development of insulin resistance and chronic cardiometabolic diseases. ASAT = abdominal subcutaneous adipose tissue; FSAT = femoral subcutaneous adipose tissue; VAT = visceral adipose tissue.

/WebMaterial/ShowPic/844839

Importantly, the inability to increase adipose tissue mass through adipocyte hyperplasia will evoke adipocyte hypertrophy during a prolonged positive energy balance. It is well established that enlargement of adipocytes is a key characteristic of adipose tissue dysfunction [22,24,25]. Hypertrophic adipocytes have a markedly impaired capacity to rapidly store dietary fat, because they are already overloaded with stored lipids, which results in a redirection of lipids towards other metabolic organs. In addition, hypertrophic adipose tissue is characterized by infiltration of adaptive and innate immune cells and altered adipokine secretion. Together, these disturbances may lead to the development of peripheral insulin resistance [22,24,25].

One reason for the discrepancy in cardiometabolic disease risk between upper-body and lower-body obesity is that abdominal fat depots are characterized by rapid uptake and storage of energy from the diet and a high lipid turnover (i.e., lipolysis), whereas the lower-body fat stores have a reduced lipid turnover rate and sequester lipids that would otherwise be directed towards non-adipose tissues [30,31]. In other words, the lower body fat seems to have a higher lipid buffering capacity and retains fatty acids well, thereby acting as a protective ‘metabolic sink'. Differences in energy storage between subcutaneous and visceral adipose tissue following meal ingestion have not been examined directly since assessment of metabolite fluxes (arterio-venous concentrations gradients) across human visceral adipose tissue is unfortunately not feasible. Only few studies have investigated potential differences in the inflammatory phenotype of upper-body and lower-body adipose tissue, showing no major differences in gene expression of inflammatory markers between abdominal subcutaneous and gluteal adipose tissue [19,32]. However, it has recently been demonstrated that in vivo IL-6 release from gluteofemoral adipose tissue was markedly lower than from the corresponding abdominal subcutaneous fat depot both in men and women [19], suggesting that lower-body fat may have a more beneficial inflammatory phenotype. Noteworthy, human abdominal subcutaneous adipose tissue is divided by the Scarpa's fascia into deep and superficial abdominal subcutaneous adipose tissue layers that have different structural and functional properties. It has been demonstrated that deep abdominal subcutaneous adipose tissue has a higher expression of pro-inflammatory, lipogenic and lipolytic genes, and contains higher proportions of saturated fatty acids and an increased proportion of small adipocytes [33,34]. The latter finding is in line with greater adipogenic potential and lower PPAR-γ DNA methylation levels in abdominal superficial as compared to deep-layer adipocytes [35]. Moreover, deep abdominal subcutaneous adipose tissue seems to expand disproportionally more than the superficial fat depot with increasing obesity, which predisposed toward whole-body insulin resistance and increased cardiovascular risk independent of other adiposity measures in men [34].

Future studies are required to assess potential differences in the phenotype of upper-body and lower-body adipose tissue, and to unravel underlying mechanisms. To conclude, these findings emphasize the central role of adipose tissue function in cardiometabolic disease risk.

Adipose Tissue Oxygen Partial Pressure

Recent studies suggest that adipose tissue oxygenation, which is determined by the local balance between oxygen supply and oxygen consumption, may be a key factor determining the adipose tissue phenotype, as extensively reviewed elsewhere [36,37,38,39]. Although the number of studies in which adipose tissue oxygen partial pressure (AT PO2) has been measured is very limited, several lines of evidence suggest that AT PO2 is reduced in rodent models of obesity [40,41,42]. Importantly, the models used in these studies do not reflect human physiology, as discussed previously [36,37]. The first study investigating abdominal subcutaneous adipose tissue oxygenation in obese and lean individuals supported the available data in rodents, showing lower AT PO2 in obesity [43]. However, we have challenged the concept of adipose tissue ‘hypoxia' in human obesity, demonstrating that AT PO2 was higher rather than lower in obese compared to lean subjects, despite lower blood flow (oxygen supply), and was associated with adipose tissue inflammation and peripheral insulin resistance [44]. A diet-induced weight loss study that we have very recently performed in our laboratory substantiates the latter findings. Environmental hypoxia exposure decreases the partial pressure of arterial oxygen, and as such reduces oxygen supply to peripheral tissues, including adipose tissue [45]. Interestingly, exposure to moderate hypoxia for 10 subsequent nights increased whole-body insulin sensitivity in a small group of obese individuals [46] which may at least partly be explained by decreased AT PO2[44]. Future studies are required to establish the importance of the adipose tissue oxygenation in metabolic health.

Metabolically Healthy Obesity: A Misleading Concept?

Intriguingly, expansion of adipose tissue does not necessarily translate into metabolic abnormalities. A subset of obese individuals (∼10-30% of obese individuals) [47], often referred to as ‘metabolically healthy obese' (MHO), seems to be relatively protected against worsening of metabolic health (fig. 1). Since the criteria to classify MHO as well as the cut-off values for these parameters have only recently been established [47], most studies performed thus far have defined MHO as the absence of metabolic disturbances, including dyslipidemia, insulin resistance, impaired glucose metabolism, and overt type 2 diabetes [47,48,49,50]. However, it can be debated whether MHO individuals are really healthy since several recently performed meta-analyses of prospective cohort studies have shown that the majority of MHO subjects have a markedly increased risk of developing type 2 diabetes [51] and cardiovascular disease [52,53] over time as compared to healthy normal weight subjects. Strikingly, one of these meta-analyses has shown that metabolically healthy obesity was not associated with mortality and increased cardiovascular events compared with metabolically healthy normal weight when all studies were included. Notably, however, a 24% increased risk was found when only studies with follow-up periods longer than 10 years were included in the analysis [53]. In line, Appleton and colleagues [54] have demonstrated that MHO is a transient phenotype in about one-third of the MHO subjects. Interestingly, the latter study demonstrated that persistence of a MHO phenotype during 5.5-10.3 years of follow-up, which was related to younger age and lower central adiposity, was associated with comparable risks for diabetes and cardiovascular disease as seen in metabolically healthy normal weight subjects [54]. Therefore, it seems that the majority of MHO individuals is clearly on the way to becoming ‘unhealthy' obese. Noteworthy, MHO individuals may also have a reduced quality of life due to an increased prevalence of other obesity-related comorbidities such as psychological abnormalities, osteoarthritis, respiratory diseases, gynecologic abnormalities, and skin problems. Indeed, a pooled analysis of 8 cross-sectional studies has demonstrated that MHO individuals have an increased risk of depressive symptoms [55]. These data indicate that major efforts should be made to prevent obesity and to maintain a metabolically healthy phenotype in subjects that already have developed obesity.

The key role of adipose tissue function in metabolic health becomes furthermore apparent when comparing obese insulin sensitive (MHO) and obese insulin resistant individuals. MHO subjects are characterized by more abdominal subcutaneous adipose tissue, lower visceral fat mass, less fat accumulation in liver and skeletal muscle, smaller (more insulin sensitive) adipocytes, less macrophage infiltration and inflammation in (visceral) adipose tissue, and a more favorable inflammatory profile as compared to metabolically unhealthy obese persons, matched for age, gender, BMI, and fat mass [48,49,56,57] (fig. 1). In addition, it seems that the physical fitness level is an important determinant of the metabolic phenotype in obese individuals [58]. Together, these findings may imply that stratification of obese subjects based on metabolic health may be necessary to optimize prevention and treatment strategies, and it provides a tool to better understand the role of adipose tissue function and other potential biological mechanisms in obesity-related complications. Indeed, there is some evidence that risk stratification at baseline improves the effectiveness of a certain intervention in a particular subgroup of the population [59]. This is exemplified by a recent analysis of data from the TULIP study, demonstrating that stratification of subjects with prediabetes by phenotype (including impaired insulin secretion, insulin resistance, and non-alcoholic fatty liver) at baseline predicts the effectiveness of a lifestyle intervention to achieve normal glucose homeostasis. More specific, the latter study demonstrated that a high-risk phenotype at baseline was associated with reduced improvement in glycemia following lifestyle intervention [60].

Conclusions

BMI and body fat mass are important determinants of metabolic health at the population level. Body fat distribution and adipose tissue dysfunction, which may partly be explained by altered adipose tissue oxygenation, are key factors in the development of obesity-related insulin resistance and cardiometabolic diseases and better predict disease risk at the individual level. Although MHO individuals are relatively protected against chronic diseases as compared to metabolically unhealthy individuals, which is at least partly due to a better adipose tissue function and less ectopic fat storage, they do have a markedly increased risk of developing obesity-related diseases in comparison with normal weight individuals. Therefore, ‘metabolically healthy' obesity should not be regarded as a harmless condition. Studies to further unravel the mechanisms underlying the protective properties of adipose tissue in MHO will be invaluable in obtaining a better understanding of the pathophysiology of insulin resistance and cardiometabolic diseases. Detailed metabolic phenotyping, including tissue-specific profiling, is essential to identify individuals or subgroups at increased risk of developing metabolic diseases, and to optimize prevention and treatment strategies.

Acknowledgments

The author would like to thank the European Foundation for the Study of Diabetes (Clinical Research Grant to G.H.G., 2013) and the Dutch Diabetes Research Foundation (Senior Fellowship Grant 2015.82.1818 to G.H.G.) for financial support.

Disclosure Statement

The author has not declared any conflicts of interest.


References

  1. Kopelman PG: Obesity as a medical problem. Nature 2000;404:635-643.
  2. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19.
  3. Bergman RN, Ader M, Huecking K, Van Citters G: Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 2002;51(suppl 1):S212-220.
  4. Blundell JE, Dulloo AG, Salvador J, Fruhbeck G: Beyond BMI - phenotyping the obesities. Obes Facts 2014;7:322-328.
  5. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L: Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care 2008;11:693-700.
  6. The Global BMI Mortality Collaboration: Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-786.
  7. Rush EC, Goedecke JH, Jennings C, Micklesfield L, Dugas L, Lambert EV, Plank LD: BMI, fat and muscle differences in urban women of five ethnicities from two countries. Int J Obes (Lond) 2007;31:1232-1239.
  8. Unnikrishnan R, Anjana RM, Mohan V: Diabetes in South Asians: is the phenotype different? Diabetes 2014;63:53-55.
  9. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS: Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004;350:2549-2557.
  10. Fonseca V: Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003;115(suppl 8A):42S-48S.
  11. Ganda OP: Lipoatrophy, lipodystrophy, and insulin resistance. Ann Intern Med 2000;133:304-306.
  12. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI: Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 2000;275:8456-8460.
  13. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML: Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000;105:271-278.
  14. Wells JC: Sexual dimorphism of body composition. Best Pract Res Clin Endocrinol Metab 2007;21:415-430.
  15. Horber FF, Zurcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ: Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr 1986;43:758-769.
    External Resources
  16. Malis C, Rasmussen EL, Poulsen P, Petersen I, Christensen K, Beck-Nielsen H, Astrup A, Vaag AA: Total and regional fat distribution is strongly influenced by genetic factors in young and elderly twins. Obes Res 2005;13:2139-2145.
  17. Hilton C, Karpe F, Pinnick KE: Role of developmental transcription factors in white, brown and beige adipose tissues. Biochim Biophys Acta 2015;1851:686-696.
  18. White UA, Tchoukalova YD: Sex dimorphism and depot differences in adipose tissue function. Biochim Biophys Acta 2014;1842:377-392.
  19. Pinnick KE, Nicholson G, Manolopoulos KN, McQuaid SE, Valet P, Frayn KN, Denton N, Min JL, Zondervan KT, Fleckner J, McCarthy MI, Holmes CC, Karpe F: Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 2014;63:3785-3797.
  20. Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE: Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord 2004;28:402-409.
  21. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-1649.
  22. Goossens GH: The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008;94:206-218.
  23. Frayn KN: Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001;60:375-380.
    External Resources
  24. Rosen ED, Spiegelman BM: What we talk about when we talk about fat. Cell 2014;156:20-44.
  25. Stinkens R, Goossens GH, Jocken JW, Blaak EE: Targeting fatty acid metabolism to improve glucose metabolism. Obes Rev 2015;16:715-757.
  26. Virtue S, Vidal-Puig A: Adipose tissue expandability, lipotoxicity and the metabolic syndrome - an allostatic perspective. Biochim Biophys Acta 2010;1801:338-349.
  27. Johannsen DL, Tchoukalova Y, Tam CS, Covington JD, Xie W, Schwarz JM, Bajpeyi S, Ravussin E: Effect of 8 weeks of overfeeding on ectopic fat deposition and insulin sensitivity: testing the ‘adipose tissue expandability' hypothesis. Diabetes Care 2014;37:2789-2797.
  28. Hardy OT, Czech MP, Corvera S: What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes 2012;19:81-87.
  29. Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, Scherer PE: Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab 2014;20:103-118.
  30. Karpe F, Pinnick KE: Biology of upper-body and lower-body adipose tissue - link to whole-body phenotypes. Nat Rev Endocrinol 2015;11:90-100.
  31. Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, Kirkland JL: Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 2013;17:644-656.
  32. Malisova L, Rossmeislova L, Kovacova Z, Kracmerova J, Tencerova M, Langin D, Siklova-Vitkova M, Stich V: Expression of inflammation-related genes in gluteal and abdominal subcutaneous adipose tissue during weight-reducing dietary intervention in obese women. Physiol Res 2014;63:73-82.
    External Resources
  33. Cancello R, Zulian A, Gentilini D, Maestrini S, Della Barba A, Invitti C, Cora D, Caselle M, Liuzzi A, Di Blasio AM: Molecular and morphologic characterization of superficial- and deep-subcutaneous adipose tissue subdivisions in human obesity. Obesity (Silver Spring) 2013;21:2562-2570.
  34. Marinou K, Hodson L, Vasan SK, Fielding BA, Banerjee R, Brismar K, Koutsilieris M, Clark A, Neville MJ, Karpe F: Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care 2014;37:821-829.
  35. Kosaka K, Kubota Y, Adachi N, Akita S, Sasahara Y, Kira T, Kuroda M, Mitsukawa N, Bujo H, Satoh K: Human adipocytes from the subcutaneous superficial layer have greater adipogenic potential and lower PPAR-gamma DNA methylation levels than deep layer adipocytes. Am J Physiol Cell Physiol 2016;311:C322-329.
  36. Goossens GH, Blaak EE: Adipose tissue oxygen tension: implications for chronic metabolic and inflammatory diseases. Curr Opin Clin Nutr Metab Care 2012;15:539-546.
  37. Goossens GH, Blaak EE: Adipose tissue dysfunction and impaired metabolic health in human obesity: a matter of oxygen? Front Endocrinol (Lausanne) 2015;6:55.
  38. Trayhurn P: Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev 2013;93:1-21.
  39. Trayhurn P: Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. Annu Rev Nutr 2014;34:207-236.
  40. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV: Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes 2008;32:451-463.
  41. Ye J, Gao Z, Yin J, He Q: Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007;293:E1118-1128.
  42. Yin J, Gao Z, He Q, Zhou D, Guo Z, Ye J: Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. Am J Physiol Endocrinol Metab 2009;296:E333-342.
  43. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR: Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009;58:718-725.
  44. Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, Jocken JW, Cajlakovic M, Ribitsch V, Clement K, Blaak EE: Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation 2011;124:67-76.
  45. Reinke C, Bevans-Fonti S, Drager LF, Shin MK, Polotsky VY: Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J Appl Physiol (1985) 2011;111:881-890.
  46. Lecoultre V, Peterson CM, Covington JD, Ebenezer PJ, Frost EA, Schwarz JM, Ravussin E: Ten nights of moderate hypoxia improves insulin sensitivity in obese humans. Diabetes Care 2013;36:e197-198.
  47. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, Gaye A, Gogele M, Heier M, Hiekkalinna T, Joensuu A, Newby C, Pang C, Partinen E, Reischl E, Schwienbacher C, Tammesoo ML, Swertz MA, Burton P, Ferretti V, Fortier I, Giepmans L, Harris JR, Hillege HL, Holmen J, Jula A, Kootstra-Ros JE, Kvaloy K, Holmen TL, Mannisto S, Metspalu A, Midthjell K, Murtagh MJ, Peters A, Pramstaller PP, Saaristo T, Salomaa V, Stolk RP, Uusitupa M, van der Harst P, van der Klauw MM, Waldenberger M, Perola M, Wolffenbuttel BH: The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord 2014;14:9.
  48. Bluher M: Are metabolically healthy obese individuals really healthy? Eur J Endocrinol 2014;171:R209-219.
  49. Stefan N, Haring HU, Hu FB, Schulze MB: Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 2013;1:152-162.
  50. Bluher M: Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab 2013;27:163-177.
  51. Bell JA, Kivimaki M, Hamer M: Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev 2014;15:504-515.
  52. Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB: Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. Eur J Prev Cardiol 2016;23:956-966.
  53. Kramer CK, Zinman B, Retnakaran R: Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 2013;159:758-769.
  54. Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW, Adams RJ: Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 2013;36:2388-2394.
  55. Jokela M, Hamer M, Singh-Manoux A, Batty GD, Kivimaki M: Association of metabolically healthy obesity with depressive symptoms: pooled analysis of eight studies. Mol Psychiatry 2014;19:910-914.
  56. Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, Stumvoll M, Blüher M: Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010;299:E506-515.
  57. Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V, Sladek R, Rabasa-Lhoret R: Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond) 2011;35:971-981.
  58. Lavie CJ, De Schutter A, Milani RV: Healthy obese versus unhealthy lean: the obesity paradox. Nat Rev Endocrinol 2015;11:55-62.
  59. Stefan N, Fritsche A, Schick F, Haring HU: Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 2016;4:789-798.
  60. Stefan N, Staiger H, Wagner R, Machann J, Schick F, Haring HU, Fritsche A: A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes. Diabetologia 2015;58:2877-2884.

Author Contacts

Gijs H. Goossens, PhD

Department of Human Biology

NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center

PO Box 616, 6200 MD, Maastricht, The Netherlands

G.Goossens@maastrichtuniversity.nl


Article / Publication Details

First-Page Preview
Abstract of Review Article

Received: October 27, 2016
Accepted: March 09, 2017
Published online: June 01, 2017
Issue release date: June 2017

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 0

ISSN: 1662-4025 (Print)
eISSN: 1662-4033 (Online)

For additional information: http://www.karger.com/OFA


Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kopelman PG: Obesity as a medical problem. Nature 2000;404:635-643.
  2. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19.
  3. Bergman RN, Ader M, Huecking K, Van Citters G: Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 2002;51(suppl 1):S212-220.
  4. Blundell JE, Dulloo AG, Salvador J, Fruhbeck G: Beyond BMI - phenotyping the obesities. Obes Facts 2014;7:322-328.
  5. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L: Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care 2008;11:693-700.
  6. The Global BMI Mortality Collaboration: Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-786.
  7. Rush EC, Goedecke JH, Jennings C, Micklesfield L, Dugas L, Lambert EV, Plank LD: BMI, fat and muscle differences in urban women of five ethnicities from two countries. Int J Obes (Lond) 2007;31:1232-1239.
  8. Unnikrishnan R, Anjana RM, Mohan V: Diabetes in South Asians: is the phenotype different? Diabetes 2014;63:53-55.
  9. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS: Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004;350:2549-2557.
  10. Fonseca V: Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003;115(suppl 8A):42S-48S.
  11. Ganda OP: Lipoatrophy, lipodystrophy, and insulin resistance. Ann Intern Med 2000;133:304-306.
  12. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI: Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 2000;275:8456-8460.
  13. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML: Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000;105:271-278.
  14. Wells JC: Sexual dimorphism of body composition. Best Pract Res Clin Endocrinol Metab 2007;21:415-430.
  15. Horber FF, Zurcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ: Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr 1986;43:758-769.
    External Resources
  16. Malis C, Rasmussen EL, Poulsen P, Petersen I, Christensen K, Beck-Nielsen H, Astrup A, Vaag AA: Total and regional fat distribution is strongly influenced by genetic factors in young and elderly twins. Obes Res 2005;13:2139-2145.
  17. Hilton C, Karpe F, Pinnick KE: Role of developmental transcription factors in white, brown and beige adipose tissues. Biochim Biophys Acta 2015;1851:686-696.
  18. White UA, Tchoukalova YD: Sex dimorphism and depot differences in adipose tissue function. Biochim Biophys Acta 2014;1842:377-392.
  19. Pinnick KE, Nicholson G, Manolopoulos KN, McQuaid SE, Valet P, Frayn KN, Denton N, Min JL, Zondervan KT, Fleckner J, McCarthy MI, Holmes CC, Karpe F: Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 2014;63:3785-3797.
  20. Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE: Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord 2004;28:402-409.
  21. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-1649.
  22. Goossens GH: The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008;94:206-218.
  23. Frayn KN: Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001;60:375-380.
    External Resources
  24. Rosen ED, Spiegelman BM: What we talk about when we talk about fat. Cell 2014;156:20-44.
  25. Stinkens R, Goossens GH, Jocken JW, Blaak EE: Targeting fatty acid metabolism to improve glucose metabolism. Obes Rev 2015;16:715-757.
  26. Virtue S, Vidal-Puig A: Adipose tissue expandability, lipotoxicity and the metabolic syndrome - an allostatic perspective. Biochim Biophys Acta 2010;1801:338-349.
  27. Johannsen DL, Tchoukalova Y, Tam CS, Covington JD, Xie W, Schwarz JM, Bajpeyi S, Ravussin E: Effect of 8 weeks of overfeeding on ectopic fat deposition and insulin sensitivity: testing the ‘adipose tissue expandability' hypothesis. Diabetes Care 2014;37:2789-2797.
  28. Hardy OT, Czech MP, Corvera S: What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes 2012;19:81-87.
  29. Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, Scherer PE: Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab 2014;20:103-118.
  30. Karpe F, Pinnick KE: Biology of upper-body and lower-body adipose tissue - link to whole-body phenotypes. Nat Rev Endocrinol 2015;11:90-100.
  31. Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, Kirkland JL: Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 2013;17:644-656.
  32. Malisova L, Rossmeislova L, Kovacova Z, Kracmerova J, Tencerova M, Langin D, Siklova-Vitkova M, Stich V: Expression of inflammation-related genes in gluteal and abdominal subcutaneous adipose tissue during weight-reducing dietary intervention in obese women. Physiol Res 2014;63:73-82.
    External Resources
  33. Cancello R, Zulian A, Gentilini D, Maestrini S, Della Barba A, Invitti C, Cora D, Caselle M, Liuzzi A, Di Blasio AM: Molecular and morphologic characterization of superficial- and deep-subcutaneous adipose tissue subdivisions in human obesity. Obesity (Silver Spring) 2013;21:2562-2570.
  34. Marinou K, Hodson L, Vasan SK, Fielding BA, Banerjee R, Brismar K, Koutsilieris M, Clark A, Neville MJ, Karpe F: Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care 2014;37:821-829.
  35. Kosaka K, Kubota Y, Adachi N, Akita S, Sasahara Y, Kira T, Kuroda M, Mitsukawa N, Bujo H, Satoh K: Human adipocytes from the subcutaneous superficial layer have greater adipogenic potential and lower PPAR-gamma DNA methylation levels than deep layer adipocytes. Am J Physiol Cell Physiol 2016;311:C322-329.
  36. Goossens GH, Blaak EE: Adipose tissue oxygen tension: implications for chronic metabolic and inflammatory diseases. Curr Opin Clin Nutr Metab Care 2012;15:539-546.
  37. Goossens GH, Blaak EE: Adipose tissue dysfunction and impaired metabolic health in human obesity: a matter of oxygen? Front Endocrinol (Lausanne) 2015;6:55.
  38. Trayhurn P: Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev 2013;93:1-21.
  39. Trayhurn P: Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. Annu Rev Nutr 2014;34:207-236.
  40. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV: Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes 2008;32:451-463.
  41. Ye J, Gao Z, Yin J, He Q: Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007;293:E1118-1128.
  42. Yin J, Gao Z, He Q, Zhou D, Guo Z, Ye J: Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. Am J Physiol Endocrinol Metab 2009;296:E333-342.
  43. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR: Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009;58:718-725.
  44. Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, Jocken JW, Cajlakovic M, Ribitsch V, Clement K, Blaak EE: Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation 2011;124:67-76.
  45. Reinke C, Bevans-Fonti S, Drager LF, Shin MK, Polotsky VY: Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J Appl Physiol (1985) 2011;111:881-890.
  46. Lecoultre V, Peterson CM, Covington JD, Ebenezer PJ, Frost EA, Schwarz JM, Ravussin E: Ten nights of moderate hypoxia improves insulin sensitivity in obese humans. Diabetes Care 2013;36:e197-198.
  47. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, Gaye A, Gogele M, Heier M, Hiekkalinna T, Joensuu A, Newby C, Pang C, Partinen E, Reischl E, Schwienbacher C, Tammesoo ML, Swertz MA, Burton P, Ferretti V, Fortier I, Giepmans L, Harris JR, Hillege HL, Holmen J, Jula A, Kootstra-Ros JE, Kvaloy K, Holmen TL, Mannisto S, Metspalu A, Midthjell K, Murtagh MJ, Peters A, Pramstaller PP, Saaristo T, Salomaa V, Stolk RP, Uusitupa M, van der Harst P, van der Klauw MM, Waldenberger M, Perola M, Wolffenbuttel BH: The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord 2014;14:9.
  48. Bluher M: Are metabolically healthy obese individuals really healthy? Eur J Endocrinol 2014;171:R209-219.
  49. Stefan N, Haring HU, Hu FB, Schulze MB: Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 2013;1:152-162.
  50. Bluher M: Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab 2013;27:163-177.
  51. Bell JA, Kivimaki M, Hamer M: Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev 2014;15:504-515.
  52. Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB: Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. Eur J Prev Cardiol 2016;23:956-966.
  53. Kramer CK, Zinman B, Retnakaran R: Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 2013;159:758-769.
  54. Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW, Adams RJ: Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 2013;36:2388-2394.
  55. Jokela M, Hamer M, Singh-Manoux A, Batty GD, Kivimaki M: Association of metabolically healthy obesity with depressive symptoms: pooled analysis of eight studies. Mol Psychiatry 2014;19:910-914.
  56. Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, Stumvoll M, Blüher M: Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010;299:E506-515.
  57. Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V, Sladek R, Rabasa-Lhoret R: Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond) 2011;35:971-981.
  58. Lavie CJ, De Schutter A, Milani RV: Healthy obese versus unhealthy lean: the obesity paradox. Nat Rev Endocrinol 2015;11:55-62.
  59. Stefan N, Fritsche A, Schick F, Haring HU: Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 2016;4:789-798.
  60. Stefan N, Staiger H, Wagner R, Machann J, Schick F, Haring HU, Fritsche A: A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes. Diabetologia 2015;58:2877-2884.
ppt logo Download Images (.pptx)


Figures
Thumbnail

Tables